{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:07:02Z","timestamp":1791655622719,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40262-026-01645-1","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:52:54Z","timestamp":1779385974000},"page":"1027-1042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advancing Precision Dosing of 5-FU: Population PK Model Development, Limited Sampling Strategies, and Fit-for-Use Application"],"prefix":"10.1007","volume":"65","author":[{"given":"Zhiyuan","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymara","family":"Sancho-Araiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swantje","family":"V\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda L. J.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Manten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Gerard","family":"Maring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre M.","family":"Bet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A. A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherijne A. J.","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":false,"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"1645_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-Fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107447.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1645_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clcc.2014.11.002","volume":"14","author":"B Gustavsson","year":"2015","unstructured":"Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll H-J, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14(1):1\u201310. https:\/\/doi.org\/10.1016\/j.clcc.2014.11.002.","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"1645_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/s1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801\u201310. https:\/\/doi.org\/10.1016\/s1470-2045(16)00172-8.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1645_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092679","volume":"12","author":"J Taieb","year":"2020","unstructured":"Taieb J, Gallois C. Adjuvant chemotherapy for stage III colon cancer. Cancers. 2020;12(9):2679. https:\/\/doi.org\/10.3390\/cancers12092679.","journal-title":"Cancers"},{"issue":"8","key":"1645_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0820-4","volume":"21","author":"FM Johnston","year":"2019","unstructured":"Johnston FM, Beckman M. Updates on management of gastric cancer. Curr Oncol Rep. 2019;21(8):67. https:\/\/doi.org\/10.1007\/s11912-019-0820-4.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"1645_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101201","volume":"8","author":"M Li","year":"2023","unstructured":"Li M, Mindt S, L\u00fcck A, Hutzschenreuter U, Kollendt M, Lathan B, et al. Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy: results of a prospective, multicenter German observational study. ESMO Open. 2023;8(2):101201. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101201.","journal-title":"ESMO Open"},{"issue":"4","key":"1645_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.4.1105","volume":"17","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M, Gu\u00e9rin-Meyer V, Delva R, Lortholary A, Genevieve F, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol. 1999;17(4):1105. https:\/\/doi.org\/10.1200\/jco.1999.17.4.1105.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1645_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/(sici)1097-0142(19960201)77:3<441::Aid-cncr4>3.0.Co;2-n","volume":"77","author":"EC Gamelin","year":"1996","unstructured":"Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer. 1996;77(3):441\u201351. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19960201)77:3%3c441::Aid-cncr4%3e3.0.Co;2-n.","journal-title":"Cancer"},{"issue":"3","key":"1645_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/cpt.1124","volume":"105","author":"JH Beumer","year":"2019","unstructured":"Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, et al. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther. 2019;105(3):598\u2013613. https:\/\/doi.org\/10.1002\/cpt.1124.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1645_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","volume":"17","author":"RR Kaldate","year":"2012","unstructured":"Kaldate RR, Haregewoin A, Grier CE, Hamilton SA, McLeod HL. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist. 2012;17(3):296\u2013302. https:\/\/doi.org\/10.1634\/theoncologist.2011-0357.","journal-title":"Oncologist"},{"issue":"4","key":"1645_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.clcc.2016.04.001","volume":"15","author":"M Wilhelm","year":"2016","unstructured":"Wilhelm M, Mueller L, Miller MC, Link K, Holdenrieder S, Bertsch T, et al. Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice. Clin Colorectal Cancer. 2016;15(4):381\u20138. https:\/\/doi.org\/10.1016\/j.clcc.2016.04.001.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"1645_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-018-3722-5","volume":"83","author":"L Deyme","year":"2019","unstructured":"Deyme L, Barbolosi D, Gattacceca F. Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters. Cancer Chemother Pharmacol. 2019;83(1):27\u201342. https:\/\/doi.org\/10.1007\/s00280-018-3722-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1645_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s002800050980","volume":"44","author":"F Bressolle","year":"1999","unstructured":"Bressolle F, Joulia JM, Pinguet F, Ychou M, Astre C, Duffour J, et al. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 1999;44(4):295\u2013302. https:\/\/doi.org\/10.1007\/s002800050980.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1645_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","volume":"71","author":"F Mueller","year":"2013","unstructured":"Mueller F, B\u00fcchel B, K\u00f6berle D, Sch\u00fcrch S, Pfister B, Kr\u00e4henb\u00fchl S, et al. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol. 2013;71(2):361\u201370. https:\/\/doi.org\/10.1007\/s00280-012-2018-4.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1645_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1191\/1078155204jp129oa","volume":"10","author":"B Porta-Oltra","year":"2004","unstructured":"Porta-Oltra B, P\u00e9rez-Ruixo JJ, Climente-Mart\u00ed M, Merino-Sanju\u00e1n M, Almenar-Cubells D, Jim\u00e9nez-Torres NV. Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients. J Oncol Pharm Pract. 2004;10(3):155\u201367. https:\/\/doi.org\/10.1191\/1078155204jp129oa.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"1645_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1067\/mcp.2000.109352","volume":"68","author":"C Terret","year":"2000","unstructured":"Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, F\u00e9ty-Deporte R. Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther. 2000;68(3):270\u20139. https:\/\/doi.org\/10.1067\/mcp.2000.109352.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1645_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF03257473","volume":"51","author":"ABP van Kuilenburg","year":"2012","unstructured":"van Kuilenburg ABP, H\u00e4usler P, Schalhorn A, Tanck MWT, Proost JH, et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a C.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet. 2012;51(3):163\u201374. https:\/\/doi.org\/10.1007\/BF03257473.","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"1645_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2174\/156802612803531414","volume":"12","author":"C Woloch","year":"2012","unstructured":"Woloch C, Di Paolo A, Marouani H, Bocci G, Ciccolini J, Lacarelle B, et al. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. Curr Top Med Chem. 2012;12(15):1713\u20139. https:\/\/doi.org\/10.2174\/156802612803531414.","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"1645_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-025-04759-8","volume":"95","author":"MA Hanrath","year":"2025","unstructured":"Hanrath MA, Banken E, van den Wildenberg SAH, van de Kerkhof D, Moes D, Boisdron-Celle M, et al. Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial). Cancer Chemother Pharmacol. 2025;95(1):34. https:\/\/doi.org\/10.1007\/s00280-025-04759-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1645_CR20","unstructured":"Catharina Ziekenhuis E, Thomas M. Therapeutic oncolytic monitoring as a tool for effective exposure to 5\u2011FU in patients with locally advanced, resectable gastric or gastro\u2011oesophageal junction cancer treated with perioperative FLOT. ClinicalTrials.gov, Bethesda (MD), 2022. https:\/\/clinicaltrials.gov\/study\/NCT05620524. Accessed 20 Apr 2025."},{"key":"1645_CR21","unstructured":"Manten T Fiebrich-Westra H-B, Creemers GJ, Largiad\u00e8r CR, Robyr T, et al. Therapeutic drug monitoring and dried blood spot measurements of 5-fluorouracil as 24-hour infusion in patients with gastric cancer treated with perioperative FLOT. Abstract for 22nd International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Banff, Alberta, Canada, September 15\u201318, 2024."},{"key":"1645_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/po-25-00062","volume":"9","author":"H-B Fiebrich-Westra","year":"2025","unstructured":"Fiebrich-Westra H-B, Haroun C, van der Gali\u00ebn R, den Besten-Bertholee D, Deenen MJ, Moes DJAR, et al. Precision treatment of patients with GI cancer using pre-emptive DPYD genotyping\/phenotyping plus pharmacokinetic-guided dosing of 5-fluorouracil. JCO Precis Oncol. 2025;9:e2500062. https:\/\/doi.org\/10.1200\/po-25-00062.","journal-title":"JCO Precis Oncol"},{"key":"1645_CR23","unstructured":"Amsterdam UMClV, Pierre B. Personalized prediction and regulation of 5-FU exposure. 2019, EU Clinical Trials Register. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003740-77\/NL. Accessed 25 Apr 2026."},{"issue":"4","key":"1645_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"C Lunenburg","year":"2020","unstructured":"Lunenburg C, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28(4):508\u201317. https:\/\/doi.org\/10.1038\/s41431-019-0540-0.","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"1645_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"issue":"9-11","key":"1645_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/15257770600894741","volume":"25","author":"AB van Kuilenburg","year":"2006","unstructured":"van Kuilenburg AB, van Lenthe H, Maring JG, van Gennip AH. Determination of 5-fluorouracil in plasma with HPLC-tandem mass spectrometry. Nucleosides Nucleotides Nucleic Acids. 2006;25(9\u201311):1257\u201360. https:\/\/doi.org\/10.1080\/15257770600894741.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1","key":"1645_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jchromb.2005.07.023","volume":"824","author":"G Remaud","year":"2005","unstructured":"Remaud G, Boisdron-Celle M, Morel A, Gamelin A. Sensitive MS\/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma. J Chromatogr B. 2005;824(1):153\u201360. https:\/\/doi.org\/10.1016\/j.jchromb.2005.07.023.","journal-title":"J Chromatogr B"},{"issue":"3","key":"1645_CR28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1208\/s12248-011-9289-2","volume":"13","author":"A Khandelwal","year":"2011","unstructured":"Khandelwal A, Harling K, Jonsson EN, Hooker AC, Karlsson MO. A fast method for testing covariates in population PK\/PD models. AAPS J. 2011;13(3):464\u201372. https:\/\/doi.org\/10.1208\/s12248-011-9289-2.","journal-title":"AAPS J"},{"issue":"10","key":"1645_CR29","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/psp4.12829","volume":"11","author":"JF Marier","year":"2022","unstructured":"Marier JF, Teuscher N, Mouksassi MS. Evaluation of covariate effects using forest plots and introduction to the coveffectsplot R package. CPT Pharmacometr Syst Pharmacol. 2022;11(10):1283\u201393. https:\/\/doi.org\/10.1002\/psp4.12829.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"9","key":"1645_CR30","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s11095-013-1079-3","volume":"30","author":"FP Combes","year":"2013","unstructured":"Combes FP, Retout S, Frey N, Mentr\u00e9 F. Prediction of shrinkage of individual parameters using the Bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics. Pharm Res. 2013;30(9):2355\u201367. https:\/\/doi.org\/10.1007\/s11095-013-1079-3.","journal-title":"Pharm Res"},{"issue":"12","key":"1645_CR31","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/psp4.12713","volume":"10","author":"RJ Bauer","year":"2021","unstructured":"Bauer RJ, Hooker AC, Mentre F. Tutorial for $DESIGN in NONMEM: clinical trial evaluation and optimization. CPT Pharmacometrics Syst Pharmacol. 2021;10(12):1452\u201365. https:\/\/doi.org\/10.1002\/psp4.12713.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"1645_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/bja\/aex007","volume":"118","author":"M Hara","year":"2017","unstructured":"Hara M, Masui K, Eleveld DJ, Struys MMRF, Uchida O. Predictive performance of eleven pharmacokinetic models for propofol infusion in children for long-duration anaesthesia. Br J Anaesth. 2017;118(3):415\u201323. https:\/\/doi.org\/10.1093\/bja\/aex007.","journal-title":"Br J Anaesth"},{"issue":"12","key":"1645_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/psp4.12467","volume":"8","author":"A Elmokadem","year":"2019","unstructured":"Elmokadem A, Riggs MM, Baron KT. Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: A hands-on tutorial. CPT Pharmacometrics Syst Pharmacol. 2019;8(12):883\u201393. https:\/\/doi.org\/10.1002\/psp4.12467.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"1645_CR34","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/psp4.12689","volume":"10","author":"F Le Louedec","year":"2021","unstructured":"Le Louedec F, Puisset F, Thomas F, Chatelut \u00c9, White-Koning M. Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr. CPT Pharmacometrics Syst Pharmacol. 2021;10(10):1208\u201320. https:\/\/doi.org\/10.1002\/psp4.12689.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1645_CR35","doi-asserted-by":"crossref","unstructured":"Briki M, Thoueille P, Joerger M, Chatelut E, Sterle M, Decosterd LA, et al. Model-based meta-analysis of individual patient data from three independent datasets for the characterization of intravenous 5-fluorouracil population pharmacokinetics. 2024. https:\/\/www.page-meeting.org\/default.asp?abstract=10998#. Accessed 20 Apr 2026.","DOI":"10.1007\/s00280-026-04885-x"},{"issue":"12","key":"1645_CR36","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/17425255.2018.1550484","volume":"14","author":"F Goirand","year":"2018","unstructured":"Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer J-C, et al. How can we best monitor 5-FU administration to maximize benefit to risk ratio? Expert Opin Drug Metab Toxicol. 2018;14(12):1303\u201313. https:\/\/doi.org\/10.1080\/17425255.2018.1550484.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"1645_CR37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/bcp.14444","volume":"87","author":"J Jacob","year":"2021","unstructured":"Jacob J, Mathew SK, Chacko RT, Aruldhas BW, Singh A, Prabha R, et al. Systemic exposure to 5-fluorouracil and its metabolite, 5,6-dihydrofluorouracil, and development of a limited sampling strategy for therapeutic drug management of 5-fluorouracil in patients with gastrointestinal malignancy. Br J Clin Pharmacol. 2021;87(3):937\u201345. https:\/\/doi.org\/10.1111\/bcp.14444.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1645_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00007691-200206000-00016","volume":"24","author":"M Gusella","year":"2002","unstructured":"Gusella M, Ferrazzi E, Ferrari M, Padrini R. New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus. Ther Drug Monit. 2002;24(3):25\u201331. https:\/\/doi.org\/10.1097\/00007691-200206000-00016.","journal-title":"Ther Drug Monit"},{"issue":"22","key":"1645_CR39","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/jnci\/djp328","volume":"101","author":"MW Saif","year":"2009","unstructured":"Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009;101(22):1543\u201352. https:\/\/doi.org\/10.1093\/jnci\/djp328.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1645_CR40","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s40262-024-01382-3","volume":"63","author":"M Centanni","year":"2024","unstructured":"Centanni M, Reijnhout N, Thijs A, Karlsson MO, Friberg LE. Pharmacogenetic testing or therapeutic drug monitoring: a quantitative framework. Clin Pharmacokinet. 2024;63(6):871\u201384. https:\/\/doi.org\/10.1007\/s40262-024-01382-3.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1645_CR41","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","volume":"28","author":"LM Henricks","year":"2017","unstructured":"Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol. 2017;28(12):2915\u201322. https:\/\/doi.org\/10.1093\/annonc\/mdx411.","journal-title":"Ann Oncol"},{"issue":"3","key":"1645_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","volume":"78","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. 2016;78(3):447\u201364. https:\/\/doi.org\/10.1007\/s00280-016-3054-2.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1645_CR43","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"AB van Kuilenburg","year":"2004","unstructured":"van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2003.12.004.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1645_CR44","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/brm.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149\u201360. https:\/\/doi.org\/10.3758\/brm.41.4.1149.","journal-title":"Behav Res Methods"},{"issue":"7-8","key":"1645_CR45","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/0959-8049(95)00242-b","volume":"31a","author":"F L\u00e9vi","year":"1995","unstructured":"L\u00e9vi F, Giacchetti S, Adam R, Zidani R, Metzger G, Misset JL. Chronomodulation of chemotherapy against metastatic colorectal cancer: International Organization for Cancer Chronotherapy. Eur J Cancer. 1995;31a(7\u20138):1264\u201370. https:\/\/doi.org\/10.1016\/0959-8049(95)00242-b.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1645_CR46","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cpt.3181","volume":"115","author":"FZ Marok","year":"2024","unstructured":"Marok FZ, Wojtyniak J-G, Selzer D, Dallmann R, Swen JJ, Guchelaar H-J, et al. Personalized chronomodulated 5-fluorouracil treatment: a physiologically-based pharmacokinetic precision dosing approach for optimizing cancer therapy. Clin Pharmacol Ther. 2024;115(6):1282\u201392. https:\/\/doi.org\/10.1002\/cpt.3181.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1645_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1075-6","volume":"15","author":"GF Fleming","year":"2015","unstructured":"Fleming GF, Schumm P, Friberg G, Ratain MJ, Njiaju UO, Schilsky RL. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015;15(1):69. https:\/\/doi.org\/10.1186\/s12885-015-1075-6.","journal-title":"BMC Cancer"},{"key":"1645_CR48","doi-asserted-by":"crossref","unstructured":"L\u00e9vi F. Therapeutic implications of circadian rhythms in cancer patients. Mechanisms and biological significance of pulsatile hormone secretion. Novartis Foundation Symposia; 2000; p. 119\u2013142.","DOI":"10.1002\/0470870796.ch8"},{"issue":"1-2","key":"1645_CR49","first-page":"29","volume":"62","author":"H Kojima","year":"1999","unstructured":"Kojima H, Sakamoto J, Yasue M. Circadian rhythm-modulated chemotherapy with high dose 5-fluorouracil against gastrointestinal cancers: evaluation and case report. Nagoya J Med Sci. 1999;62(1\u20132):29\u201338.","journal-title":"Nagoya J Med Sci"},{"issue":"1","key":"1645_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7150\/ijms.7.48","volume":"7","author":"A Kuwahara","year":"2010","unstructured":"Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, et al. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with stage III\/IVa esophageal squamous cell carcinoma. Int J Med Sci. 2010;7(1):48\u201354. https:\/\/doi.org\/10.7150\/ijms.7.48.","journal-title":"Int J Med Sci"},{"issue":"8","key":"1645_CR51","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.bcp.2008.01.011","volume":"75","author":"H Terazono","year":"2008","unstructured":"Terazono H, Hamdan A, Matsunaga N, Hayasaka N, Kaji H, Egawa T, et al. Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: a possible mechanism of chemotherapy-induced circadian rhythm disturbances. Biochem Pharmacol. 2008;75(8):1616\u201322. https:\/\/doi.org\/10.1016\/j.bcp.2008.01.011.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1645_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s13691-021-00526-7","volume":"11","author":"LC Amorim","year":"2022","unstructured":"Amorim LC, Peixoto RD. Should we still be using bolus 5-FU prior to infusional regimens in gastrointestinal cancers? A practical review. Int Cancer Conf J. 2022;11(1):2\u20135. https:\/\/doi.org\/10.1007\/s13691-021-00526-7.","journal-title":"Int Cancer Conf J"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01645-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:36:50Z","timestamp":1783748210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01645-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01645-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Catherijne A.J. Knibbe and Dirk Jan A.R. Moes are Editorial Board members of\n                      Clinical Pharmacokinetics\n                      . They were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Zhiyuan Tan, Aymara Sancho-Araiz, Swantje V\u00f6ller, Sof\u00eda L.J. Peeters, Thomas Manten, Maarten J. Deenen, Jan Gerard Maring, Pierre M. Bet, and Ron A.A. Math\u00f4t have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All studies included in this study were approved separately with approval numbers: NL-67140.100.18, NL-81831.100.22, NL-70778.075.19, NL-71410.029.19.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All the model codes are provided in the supplementary materials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"ZT, SV, AS, CAJK, and DJARM contributed to the research design, performed the research, analyzed the data, and wrote the manuscript. ST, TM, MD, JM, PB, and RM treated patients and reviewed and revised the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}